309. Progressive myoclonus epilepsy
11 clinical trials,   15 drugs   (DrugBank: 2 drugs),   4 drug target genes,   9 drug target pathways

Searched query = "Progressive myoclonus epilepsy", "Unverricht-Lundborg disease", "Lafora disease", "Benign adult familial myoclonus epilepsy", "BAFME"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03351569
(ClinicalTrials.gov)
December 9, 201527/10/2017Intravenous Immunoglobulin for Unverricht-Lundborg Disease.Intravenous Immunoglobulin for Unverricht-Lundborg Disease: Single-patient Trial.Unverricht-Lundborg DiseaseDrug: Intravenous immunoglobulinAzienda Socio Sanitaria Territoriale di MantovaNULLActive, not recruiting18 Years25 YearsMale1Phase 3NULL
2EUCTR2007-003210-33-FI
(EUCTR)
03/08/200713/06/2007Effect of ropinirole hydrochloride in progressive myoclonic epilepsy of Unverricht–Lundborg typeEffect of ropinirole hydrochloride in progressive myoclonic epilepsy of Unverricht–Lundborg type Progressive myoclonus epilepsy of the Unverricht–Lundborg disease (ULD) type
MedDRA version: 9.1;Level: PT;Classification code 10054895;Term: Baltic myoclonic epilepsy
Trade Name: Requip
Product Name: Ropinirole hydrochloride
Other descriptive name: ROPINIROLE HYDROCHLORIDE
Department of Neurology, Turku University HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
15Finland
3EUCTR2006-000169-12-IT
(EUCTR)
26/01/200710/01/2007A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients above or equal to 16 years with genetically ascertained Unverricht-Lundborg disease. - NDA multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients above or equal to 16 years with genetically ascertained Unverricht-Lundborg disease. - ND Unverricht-Lundborg Disease
MedDRA version: 6.1;Level: PT;Classification code 10054895
Product Name: BRIVARACETAM
Product Name: BRIVARACETAM
UCB S.A. Casa MadreNULLNot RecruitingFemale: yes
Male: yes
42Finland;Netherlands;France;Italy;Sweden
4EUCTR2006-000169-12-NL
(EUCTR)
27/12/200628/09/2006A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease.A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. Patients with genetically ascertained Unverricht-Lundborg disease (ULD).
MedDRA version: 8.1;Level: LLT;Classification code 10054894;Term: Unverricht-Lundborg disease
Product Name: Brivaracetam
Product Code: ucb 34714
INN or Proposed INN: brivaracetam
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide
Product Name: Brivaracetam
Product Code: ucb 34714
INN or Proposed INN: brivaracetam
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide
UCB S.A.NULLNot RecruitingFemale: yes
Male: yes
42Finland;Netherlands;France;Italy;Sweden
5EUCTR2006-001536-46-FI
(EUCTR)
21/11/200610/10/2006A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. - ULD trialA multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. - ULD trial Patients with genetically ascertained Unverricht-Lundborg disease (ULD).
MedDRA version: 8.1;Level: LLT;Classification code 10054894;Term: Unverricht-Lundborg disease
Product Name: Brivaracetam
Product Code: ucb 34714
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-y1] butanamide
Product Name: Brivaracetam
Product Code: ucb 34714
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-y1] butanamide
Product Name: Brivaracetam
Product Code: ucb 34714
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-y1] butanamide
UCB S.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
42Finland;France
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2006-001536-46-FR
(EUCTR)
14/11/200625/08/2006A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. - ULD trialA multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. - ULD trial Patients with genetically ascertained Unverricht-Lundborg disease (ULD).
MedDRA version: 8.1;Level: LLT;Classification code 10054894;Term: Unverricht-Lundborg disease
Product Name: Brivaracetam
Product Code: ucb 34714
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-y1] butanamide
Product Name: Brivaracetam
Product Code: ucb 34714
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-y1] butanamide
Product Name: Brivaracetam
Product Code: ucb 34714
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-y1] butanamide
UCB S.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
42Finland;France
7EUCTR2006-000169-12-FR
(EUCTR)
03/11/200625/08/2006A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease.A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. Patients with genetically ascertained Unverricht-Lundborg disease (ULD).
MedDRA version: 8.1;Level: LLT;Classification code 10054894;Term: Unverricht-Lundborg disease
Product Name: Brivaracetam
Product Code: ucb 34714
INN or Proposed INN: brivaracetam
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide
Product Name: Brivaracetam
Product Code: ucb 34714
INN or Proposed INN: brivaracetam
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide
UCB S.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
42Finland;Netherlands;France;Italy;Sweden
8NCT00368251
(ClinicalTrials.gov)
November 200623/8/2006Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and AdultsA Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (= 16 Years) With Genetically Ascertained Unverricht-Lundborg DiseaseUnverricht-Lundborg DiseaseOther: Placebo;Drug: BRV 2.5 mg;Drug: BRV 25 mg;Drug: BRV 50 mgUCB PharmaNULLCompleted16 YearsN/AAll56Phase 3United States;Canada;Finland;France;Israel;Russian Federation;Serbia;Tunisia;Former Serbia and Montenegro
9NCT00357669
(ClinicalTrials.gov)
November 200625/7/2006Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and AdultsA Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (=16 Years) With Genetically Ascertained Unverricht-Lundborg DiseaseUnverricht-Lundborg DiseaseDrug: Brivaracetam 25 mg;Drug: Brivaracetam 50 mg;Other: PlaceboUCB Pharma SANULLCompleted16 YearsN/ABoth50Phase 3Finland;France;Italy;Netherlands;Réunion;Sweden;Tunisia
10EUCTR2006-000169-12-SE
(EUCTR)
06/10/200607/08/2006A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease.A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. Patients with genetically ascertained Unverricht-Lundborg disease (ULD).
MedDRA version: 8.1;Level: LLT;Classification code 10054894;Term: Unverricht-Lundborg disease
Product Name: Brivaracetam
Product Code: ucb 34714
INN or Proposed INN: brivaracetam
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide
Product Name: Brivaracetam
Product Code: ucb 34714
INN or Proposed INN: brivaracetam
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide
UCB Pharma S.A.NULLNot RecruitingFemale: yes
Male: yes
45Finland;Netherlands;France;Italy;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2006-000169-12-FI
(EUCTR)
28/09/200631/07/2006A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease.A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients (=16 years) with genetically ascertained Unverricht-Lundborg disease. Patients with genetically ascertained Unverricht-Lundborg disease (ULD).
MedDRA version: 8.1;Level: LLT;Classification code 10054894;Term: Unverricht-Lundborg disease
Product Name: Brivaracetam
Product Code: ucb 34714
INN or Proposed INN: brivaracetam
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide
Product Name: Brivaracetam
Product Code: ucb 34714
INN or Proposed INN: brivaracetam
Other descriptive name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide
UCB S.A.NULLNot RecruitingFemale: yes
Male: yes
42Finland;Netherlands;France;Italy;Sweden